Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dieter Bürkle"'
Autor:
Susanne Schnittger, Ulrike Bacher, Claudia Haferlach, Dietrich Beelen, Peter Bojko, Dieter Bürkle, Robert Dengler, Andrea Distelrath, Michael Eckart, Robert Eckert, Stefan Fries, Jan Knoblich, Georg Köchling, Hans-Peter Laubenstein, Petro Petrides, Manfred Planker, Rudolf Pihusch, Rudolf Weide, Wolfgang Kern, Torsten Haferlach
Publikováno v:
Haematologica, Vol 94, Iss 1 (2009)
Externí odkaz:
https://doaj.org/article/1a8260f57a014216b44cfb971b3d1fda
Autor:
Andreas Schmidt, Christiane Bernhardt, Dieter Bürkle, Stefan Fries, Carla V. Hannig, Kathleen Jentsch-Ullrich, Andreas Josting, Stephan Kreher, Marcel Reiser, Hans Tilman Steinmetz, Hans Tesch, Stephanie Terner, Alexander Schulte, Carl C. Crodel, Francesca Palandri, Florian H. Heidel
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Purpose The WHO 2016 re-classification of myeloproliferative neoplasms resulted in a separation of essential thrombocythemia (ET) from the pre-fibrotic and fibrotic (overt) phases of primary myelofibrosis (MF). This study reports on a chart review co
Autor:
Sebastian Stintzing, Eyck von der Heyde, Jan Wierecky, Dieter Bürkle, Helmut Forstbauer, Gerdt Hübner, Burkhard Schmidt, Jan Schroeder, Andrea Distelrath, Marion Flum, Frank Reichenbach, Dirk Arnold, Ralph M Fritsch, Armin Gerger, Susanna Hegewisch-Becker, Arndt Vogel, Anna Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald W. Prager
Publikováno v:
Journal of Clinical Oncology. 41:34-34
34 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with a poor prognosis and limited clinical data. Based on results from the BEACON CRC trial, targeted treatment with encorafenib plus cetuximab (E+C) is available as a
Autor:
Sebastian Stintzing, Gerdt Hübner, Jan Schröder, Helmut Forstbauer, Jens Kisro, Manfred Welslau, Harald Müller-Huesmann, Dieter Bürkle, Beate Krammer-Steiner, Eyck von der Heyde, Frank Reichenbach, Dirk Arnold, Ralph M Fritsch, Armin Gerger, Susanna Hegewisch-Becker, Arndt Vogel, Anna Dorothea Wagner, Thomas Winder, Dieter Koeberle, Gerald Prager
Publikováno v:
Journal of Clinical Oncology. 40:e15584-e15584
e15584 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by a poor prognosis and limited clinical data. Based on results from the phase 3 BEACON CRC trial, targeted treatment with encorafenib plus cetuximab (E+C) repr
Autor:
Dieter Bürkle
Publikováno v:
Macromolecular Symposia. 135:43-54
Autor:
R Weide, Wolfgang Kern, Dietrich W. Beelen, Jan Knoblich, Stefan Fries, R. Pihusch, Peter Bojko, Hans-Peter Laubenstein, Torsten Haferlach, Dieter Bürkle, Michael J. Eckart, Ulrike Bacher, Andrea Distelrath, Susanne Schnittger, Robert Eckert, Claudia Haferlach, Georg Köchling, Manfred Planker, Robert Dengler, Petro E. Petrides
Recently, mutations of MPL , the gene coding for the thrombopoetin receptor, were demonstrated in ~5% of cases of primary myelofibrosis (PMF) and in ~1% of all cases of essential thrombocytosis (ET).[1][1],[2][2] They represent gain-of-function mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8956eb7691b61e6c1739d07dfa6ad6e8
https://europepmc.org/articles/PMC2625421/
https://europepmc.org/articles/PMC2625421/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.